<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00010114</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068446</org_study_id>
    <secondary_id>PBTC-N04</secondary_id>
    <nct_id>NCT00010114</nct_id>
  </id_info>
  <brief_title>Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children</brief_title>
  <official_title>Gene Expression Profiling of Infant Embryonal Central Nervous System Tumors by Microarray Gene Chip Analysis: Angiogenesis, Invasion and Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pediatric Brain Tumor Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Pediatric Brain Tumor Consortium</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Genetic studies may help in understanding the genetic processes involved in the&#xD;
      development of some types of cancer.&#xD;
&#xD;
      PURPOSE: Genetic study to learn more about genes involved in the development of central&#xD;
      nervous system tumors in young children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Identify known genes that have significantly different levels of expression, using&#xD;
           microarray gene chip analysis, in infants with newly diagnosed metastatic vs&#xD;
           non-metastatic embryonal central nervous system tumors.&#xD;
&#xD;
        -  Determine the protein expression of genes identified by microarray analysis that are&#xD;
           involved in cellular functions that regulate angiogenesis, invasion, or metastasis in&#xD;
           this patient population.&#xD;
&#xD;
        -  Determine the quantity of gene expression of the confirmed translationally expressed&#xD;
           genes using semi-quantitative polymerase chain reaction.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Tumor samples are analyzed using microarray gene chip analysis. Differentially expressed&#xD;
      genes are evaluated for protein expression by standard immunohistochemistry and/or Western&#xD;
      blot analysis, and gene expression is further quantified by semi-quantitative polymerase&#xD;
      chain reaction.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 80-100 patients (20-25 with metastatic disease and 60-75&#xD;
      with non-metastatic disease) will be accrued for this study within 4-5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genes that are expressed in metastatic vs. non-metastatic tumors</measure>
    <time_frame>Prior to therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protein expression of genes found to be expressed</measure>
    <time_frame>Prior to therapy</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">83</enrollment>
  <condition>Central Nervous System Embryonal Neoplasm</condition>
  <arm_group>
    <arm_group_label>Newly diagnosed embryonal tumors</arm_group_label>
    <description>The participants in this study are infants (&lt; 3 years of age) with newly diagnosed medulloblastoma, primitive neuroectodermal tumor, or other embryonal tumor, atypical teratoid/rhabdoid tumor, intracranial germ cell tumor, or choroid plexus carcinoma who have received no prior therapy with the exception of steroids and have consented to allow research studies on banked tissue specimens</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The participants in this study are infants (&lt; 3 years of age) with newly diagnosed&#xD;
        medulloblastoma, primitive neuroectodermal tumor, or other embryonal tumor, atypical&#xD;
        teratoid/rhabdoid tumor, intracranial germ cell tumor, or choroid plexus carcinoma who have&#xD;
        received no prior therapy with the exception of steroids and have consented to allow&#xD;
        research studies on banked tissue specimens&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed, newly diagnosed, primary intracranial embryonal central&#xD;
             nervous system tumor&#xD;
&#xD;
               -  Medulloblastoma&#xD;
&#xD;
               -  Primitive neuroectodermal tumor&#xD;
&#xD;
               -  Medulloepithelioma&#xD;
&#xD;
               -  Ependymoblastoma&#xD;
&#xD;
               -  Neuroblastoma&#xD;
&#xD;
               -  Pineoblastoma&#xD;
&#xD;
               -  Atypical teratoid/rhabdoid tumor&#xD;
&#xD;
               -  Intracranial germ cell tumor&#xD;
&#xD;
               -  Choroid plexus carcinoma&#xD;
&#xD;
               -  M positive ependymoma&#xD;
&#xD;
          -  Potential enrollment on PBTC-001 therapeutic protocol&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Under 3&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior steroids allowed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobey MacDonald, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Children's National Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Cancer Center and Cancer Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105-2794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center - Seattle</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>February 2, 2001</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>July 19, 2011</last_update_submitted>
  <last_update_submitted_qc>July 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>James M. Boyett, Executive Director Operations and Biostatistics Center</name_title>
    <organization>Pediatric Brain Tumor Consortium</organization>
  </responsible_party>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

